1. Home
  2. JRS vs PLX Comparison

JRS vs PLX Comparison

Compare JRS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Real Estate Income Fund of Beneficial Interest

JRS

Nuveen Real Estate Income Fund of Beneficial Interest

SELL

Current Price

$7.48

Market Cap

210.6M

Sector

Finance

ML Signal

SELL

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

SELL

Current Price

$2.87

Market Cap

207.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
JRS
PLX
Founded
2001
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.6M
207.1M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
JRS
PLX
Price
$7.48
$2.87
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $12.00
AVG Volume (30 Days)
60.6K
★ 940.5K
Earning Date
01-01-0001
11-10-2026
Dividend Yield
★ 8.87%
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.31
Revenue
N/A
★ $52,744,000.00
Revenue This Year
N/A
$65.42
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$9.77
Revenue Growth
★ N/A
N/A
52 Week Low
$7.12
$1.65
52 Week High
$8.90
$3.19

Technical Indicators

Market Signals
Indicator
JRS
PLX
Relative Strength Index (RSI) 44.01 55.28
Support Level $7.12 $2.54
Resistance Level $8.32 $3.19
Average True Range (ATR) 0.15 0.18
MACD -0.00 0.04
Stochastic Oscillator 22.52 60.14

Price Performance

Historical Comparison
JRS
PLX

About JRS Nuveen Real Estate Income Fund of Beneficial Interest

Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund s investment objective is to provide total return through high current income and capital appreciation.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Share on Social Networks: